Development And Characterization Of The Species-Specific Liver-Chip

The early stages of drug discovery and development involve studies mandated by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency to assess the safety of a potential therapeutic compound before it advances to the clinic.

Preclinical testing requirements primarily rely on two approaches: in vitro models and in vivo studies utilizing rodent and non-rodent animal models. Current in vitro models inadequately replicate three-dimensional cellular architecture and lack physiologically relevant environments, and animal models often poorly predict human responses due to species differences. Consequently, this hampers effective nonclinical to clinical translation.

In the pharmaceutical industry, there is a growing need for preclinical models that closely mimic human physiology to facilitate a deeper understanding of drug mechanisms. Organ-Chips offer a solution, as they replicate in vivo-like functionality within a more physiologically relevant microenvironment than conventional cell-based models. Explore how the Chip-S1 system can generate a comprehensive recapitulation of the liver sinusoid.